Polycythemia rubra vera (PV) represents a clonal hematological disorder defined by an abnormal expansion of erythroid precursors and megakaryopoiesis, in particular. Ample evidence has been provided that the IL-6/IL-6R complex may be responsible for the proliferation of normal and neoplastic megakaryocytes in vitro and this fact lead us to the hypothesis, that defects in the regulation of IL-6 synthesis take part in the pathogenesis of PV. The study was carried out to determine the IL-6 serum levels and the megakaryocytic IL-6 production in patients with PV and to compare these data with the situation in hematologically healthy donors as well as in patients suffering from spurious polycythemia -smokers polyglobuly (PG). For this purpose, IL-6 serum levels were measured by ELISA and the megakaryocytic production studied by immunohistochemistry, reverse hemolytic plaque assay (RHPA) together with reverse transcription/polymerase chain reaction (RT-PCR) in highly enriched megakaryocyte preparations. In additional experiments, the influence of IL-3 stimulation and the expression of IL-6R were tested. Serum levels of IL-6 did not differ between the three groups under study. In contrast, immunohistochemistry revealed a raised proportion of megakaryocytes expressing IL-6 in PV as compared to normal donors and patients suffering from PG. The percentage of megakaryocytes actively secreting this cytokine as detected by the RHPA was 20 times greater than in both the other groups. This phenomenon was further substantiated by the fact that IL-6 mRNA could only be shown in PV megakaryocyte preparations. The regulation of IL-6 secretion appears to be abnormal in PV. Whereas in the normal and in the PG group IL-3 stimulation exerts a marked increase in megakaryocytic IL-6 secretion, PV megakaryocytes responded with a paradoxical down-regulation of IL-6 synthesis combined with the loss of IL-6R. Our data describe for the first time an abnormally raised IL-6 production by PV megakaryocytes and point towards fundamental regulatory alterations of the IL-6 synthesis in this disease.
Introduction
Polycythemia rubra vera (PV) has been characterized as a clonal disorder of the hematopoietic stem cell with consecutive trilinear proliferation resulting in a diagnostic elevation of the red blood cell mass associated with raised hemoglobin levels, slight leukocytosis and increased platelet counts. 1 Although the mechanisms by which the neoplastic clone displaces normal hematopoiesis is not known, there is some evidence that an altered cytokine regulation pattern could be an important factor in the pathogenesis of this disorder. Several studies have shown that, compared to normal progenitors, PV marrow hematopoietic cells are hypersensitive to rhIL-3 and rhGM-CSF. 2 Moreover, the increased production of IL-6, GM-CSF, M-CSF and G-CSF in murine myeloproliferative syndromes has been demonstrated. 3 In addition, in chronic myeCorrespondence: J Thiele; Fax: 0221 478 6360 Received 20 July 1998; accepted 6 November 1998 logenous leukemia (CML) IL-6 and GM-CSF act as autocrine growth factors for the neoplastic cells under in vitro conditions. 4 A wealth of data has been accumulated that IL-6 could play a crucial role in normal and neoplastic human megakaryopoiesis. 5 This assumption is supported by the finding of a PVlike morphology with striking megakaryocytic proliferation in the bone marrow of IL-6 transgenic mice. 6 Several groups have reported significant correlations between IL-6 serum or ascitic fluid levels and thrombocytosis in patients with various inflammatory and neoplastic conditions. [7] [8] [9] Moreover, abnormal IL-6 production takes part in autocrine and paracrine growth control mechanisms in chronic myelomonocytic leukemia and in some subtypes of acute myeloid leukemia. 10, 11 Possibly, the IL-6 effects are related to its well-known suppression of the apoptosis induction by cytotoxic cancer therapeutic agents, TGF-␤1, or by wild-type p53. 12, 13 In this study the IL-6 expression and secretion as well as the IL-6R expression of PV megakaryocytes was measured in comparison to a normal control group and a cohort of smokers presenting with polyglobuly (PG). In previous studies we have shown that normally megakaryocytic IL-6 secretion can be increased by IL-3 stimulation. 14 We were interested whether this behavior was also displayed by megakaryocytes in PV.
Materials and methods

Materials
After informed consent, sternal bone marrow specimens from 10 patients undergoing cardiosurgical intervention (one female, nine males, median age 61 years) and 10 patients presenting with either thrombocytosis and/or elevated erythrocyte and leukocyte counts suggesting PV (two females, eight males, median age 58 years) were obtained. Following a complete work-up of laboratory and histological data including trephine biopsies of bone marrow, five patients of the latter group were found to suffer from PV by generally accepted diagnostic criteria, 1 while the other five patients were diagnosed to present reactive changes, ie spurious polycythemiasmokers polyglobuly. None of the PV patients has been treated with chemotherapy or radio-phosphorus prior to the biopsy. A detailed list of the hematological parameters is given in Table 1 .
IL-6 quantification in the serum
An ELISA for IL-6 detection was performed by using a commercial kit (Coulter-Immunotech, Hamburg, Germany). Briefly, 96-well flat-bottom immunoplates were coated with samples, standards and enzyme conjugate, followed by the 
Immunohistochemistry
Representative bone marrow trephine biopsies were obtained from the posterior iliac crest. The samples were fixed in an aldehyde solution and further processed by decalcification for 3-4 days. 15 Before staining, all sections of paraffin-embedded marrow specimens were digested with pronase (1 mg per 1 ml Tris-buffered saline) for 30 min at 37.5°C. Monoclonal IL-6 antibodies (1618-01) were purchased from Genzyme (Boston, MA, USA). The staining was performed according to the ABC method adding 0.1% saponin. Only cells clearly identified as megakaryocytes were taken into account (see also Figure 1 ).
Marrow cell preparation
Marrow particles were immediately transferred to serum-free Iscove's medium (Gibco, Paisley, UK) containing penicillin (100 U/ml) and streptomycin (100 g/ml; Biochrom, Berlin, Germany). Marrow cells were isolated from bone particles in 30 mm culture dishes (Greiner, Frickenhausen, Germany) after gentle agitation for 4 h at 37°C in a humidified atmosphere of 5% CO 2 in air.
Megakaryocyte enrichment
Megakaryocytes were enriched by density centrifugation at 400 g over a single-density Percoll gradient (d = 1.050 g/ml; Seromed, Berlin, Germany). The interphase was collected and cells were resuspended to a final concentration of 2-3 × 10 6 cells/ml in RPMI 1640 supplemented with 0.1% BSA (Sigma, St Louis, MO, USA), penicillin (100 U/ml), and streptomycin (100 g/ml).
Preceding the RT-PCR procedure, Percoll interphase cells were incubated with a monoclonal CD61-antibody (Y2/51; 10 g/ml; Dako, Hamburg, Germany) for 10 min on ice and then subsequently stained with anti-IgG1-MACS beads (1:5 dilution; Miltenyi Biotec, Bergisch-Gladbach, Germany) for 5 min at room temperature followed by 10 min on ice. The cells were separated over a miniMACS column (Miltenyi). A more detailed description of this method has been published in a previous communication. 16 The megakaryocyte-depleted fraction was allowed to settle down on to cover plates. In the group of nonadherent cells only few CD68 positive macrophages could be detected.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Megakaryocyte preparations and megakaryocyte-depleted cell fractions were diluted to 10 5 cells/ml in RPMI 1640 medium supplemented with 0.1% BSA and penicillin/streptomycin and incubated at 37°C in a humid atmosphere with 5% CO 2 . Samples were stimulated by addition of 10 ng/ml rh-IL-3 over a period of 8 h. Total RNA was isolated according to a protocol described previously. 17 Briefly, cells were collected by centrifugation and the resulting cell pellets were lysed in 200 l of a solution containing 4 M guanidinium isothiocyanate, 25 mM sodium citrate, 0.1 M 2 mercaptoethanol, 0.5% Nlaurylsarcosine and vortexed vigorously. After extraction with water-saturated phenol, chloroform and chloroform:isoamyl alcohol (49:1 v/v), cellular RNA was precipitated by adding 70% ice-cold ethanol and subsequently extracted with isopropyl alcohol. The RNA obtained was vacuum dried and dissolved in diethyl pyrocarbonate (DEPC)-treated water to a final volume of 20 l. Reverse transcription was performed in a total volume of 20 l using oligo (dT) 15 (Promega, SERVA Feinbiochemica, Heidelberg, Germany) as primer and the reverse transcriptase Superscript II according to the instructions of the manufacturer (Gibco BRL, Eggenstein, Germany). Following reverse transcription, 3 l of the reaction solution were used for PCR amplification. The primers were designed to span large intronic gene sequences, this allowing the distinction of cDNA and genomic DNA based on the size of the amplified products. Using a hot-start technique combined with a 'touch down' temperature protocol 18 40 cycles were performed on a thermocycler (Perkin Elmer, Duesseldorf, Germany) using a sample volume of 50 l. A second round of 40 PCR cycles was performed using 10 l of the amplified material and fresh Taq polymerase. The products were separated on 5% NuSieve agarose gels containing ethidium bromide and photographed. In each experiment, controls without reverse transcriptase and with ␤-actin were performed.
Human hemopoietic cytokine
rhIL3 specific activity Ͼ2 × 10 7 U/mg protein was determined by the proliferative effect on TF1 responder cells (Genzyme, Boston, MA, USA).
Human hemopoietic cytokine neutralizing antiserum
Rabbit polyclonal antiserum to human IL-6; 80% IgG; 10-50 l/ml of antibody was used for the precipitation of rhIL-6 (Genzyme). The polyclonal antisera were able to bind to a b staphylococcus protein A as could be demonstrated in a modified protein dot blot test using protein A gold (Biotrend, Cologne, Germany).
Test conditions
Cells were either used for the RHPA immediately or incubated in rolling plastic flasks for 8 h in the presence of 10 ng/ml rhIL-3 in megakaryocyte medium. 19 
Reverse hemolytic plaque assay (RHPA)
We employed the RHPA according to modifications that have been previously described in detail. 14, 20, 21 Briefly, either freshly prepared or IL-3 stimulated megakaryocyte enriched human bone marrow cells were mixed with an equal volume of sheep red blood cells (SRBC) coupled to protein A (Sigma). Prior to conjugation procedure sheep leukocytes had been removed using a Percoll gradient method. The cell mixture was aliquoted into poly-L-lysine coated Cunningham chambers and allowed to settle on to the glass slides for 60 min at 37°C in a humidified atmosphere of 5% CO 2 in air. The excess of unattached cells was removed by rinsing each chamber with prewarmed RPMI 1640 medium containing 0.1% BSA, penicillin (100 U/ml), and streptomycin (100 g/ml). The chambers were then filled with a 1/200 (v/v) dilution of polyclonal rabbit anti-IL-6 and slides were incubated at 37°C for 6 h. Subsequently, chambers were washed with medium to remove any unbound antibody or secretagogue and were filled with a dilution of 1/50 guinea-pig complement (Gibco, Paisley, UK) to initiate plaque formation (Figure 2a-c) . Finally, cells were exposed to 0.5% (v/v) glutaraldehyde in Tris-buffered saline (TBS) for 3 min. Cover slips were removed from the chambers and the slides were rinsed in TBS and prepared for immunolabelling.
Identification of megakaryocytes
Megakaryocytes were identified by immunostaining with a monoclonal antibody (mab) recognizing platelet -glycoprotein IIIa (Y2/51 -CD61, Dako, Hamburg, Germany) 22 according to the ABC method (Figure 2a and b) . 23 
Flow cytometry
The percentage of megakaryocytes was determined with a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) (Figure 2a and b) .
Controls.
(1) Vitality of the megakaryocytes: FACScan analysis (Becton Dickinson) demonstrated the vitality and purity of the density enriched megakaryocytes by propidium iodide and immunoidentification with fluorescein thiocyanate (FITC)-coupled anti-CD61. Following the RHPA, for each patient and each stimulation condition probes of anti-CD61 stained slides were incubated with a 1:20 dilution of rhodamine-conjugated goat F(abЈ) 2 antimouse IgG (Tago, Burlingame, CA, USA) and a fluorescein diacetate solution (0.1 g/ml) for 20 min on ice according to the fluorescein diacetate method (Sigma). 24 Cells were subsequently washed and examined with a Zeiss Photoscope 3 (Carl Zeiss, Oberkochen, Germany) for both fluorescein and rhodamine fluorescence. (2) Specificity of the plaque formation: IL-6 specificity of plaque formation was determined as follows: plaque formation was not visible if (a) human marrow cells were omitted and the assay was performed using sheep red blood cells alone, (b) the specific antibodies were omitted and replaced by normal rabbit serum, (c) complement was 
Quantitative analysis
Data are presented as means ± s.e.m. Statistical analysis of the data was performed by the Mann-Whitney U test. A statistical analysis of variance between the different patients megakaryocytes was performed. As no significant differences could be calculated, pooled data are presented.
Results
In all experiments under study the normal control group (n = 10) and the patients with smokers polyglobuly (n = 5) presented similar results. Particularly, the serum IL-6 level of the PG group (mean 19.6 pg/ml, s.d. 5.2 pg/ml) was not significantly altered in comparison to the normal controls (mean 18.5 pg/ml, s.d. 6.8 pg/ml). Moreover, in the PV group, the IL-6 serum level was in the normal range as well (n = 5, mean 17.1 pg/ml, s.d. 7.7 pg/ml). Immunohistochemical analysis of trephine biopsies employing a monoclonal antibody directed against IL-6 disclosed a variable but distinctive granular reaction product throughout the cytoplasm of a megakaryocyte subpopulation. Semiquantitative analysis showed that, compared to PG and normal megakaryocytes, a greater number of this cell lineage displayed a positive intracytoplasmic staining in PV (Figure 1) .
Irrespective of the patient group, the purity of the megakaryocyte cell fraction ranged between 8 and 15% following centrifugation over a single density Percoll gradient and increased to 60-70% after immunomagnetic separation as determined by FACScan analysis. Cytospin preparations demonstrated immature cells as well as giant megakaryocytes with dense stag horn-like nuclei and large portions of granulated cytoplasm. After the enrichment procedure, 80% of the megakaryocytes were viable as indicated by the fluorescein diacetate method. The number of non-viable megakaryocytes increased to 25-35% after performing the RHPA independently of plaque formation. Medium-sized and small megakaryocytes were prevalent because of the reduced adherence of giant forms to the coated slides. Identification by immunostaining was performed with antibodies to GPIIIa (CD61), a glycoprotein known to recognize megakaryoblasts as well as mature megakaryocytes. 25, 26 The megakaryocyte-depleted cell fractions consisted predominantly of erythropoietic cells and precursors of the myeloid lineage and displayed less than 1% megakaryocytes and less than 0.5% CD68 positive macrophages.
Data on spontaneous megakaryocytic secretion of IL-6 as well as the secretion after stimulation with rhIL-3 (10 ng/mL) are shown in Figure 3 . In all samples under study, cytokine release could be clearly assessed by the ability of the immunostained megakaryocytes to form distinctive hemolytic halos in the plaque assay (see also Figure 2a and b) . Further control experiments regularly displayed hemolytic plaques surrounding cells of the BJAB cell line (Figure 2c) .
Regarding the control group, the spontaneous secretion of
Figure 3
Megakaryocyte IL-6 release. Spontaneous secretion and following addition of 10.0 ng/ml rhIL-3 on plaque formation. Number of plaque-forming cells (mean ± s.e.m.) per 10 3 megakaryocytes of pooled data (normal controls n = 10; PG group n = 5; PV group n = 5).
IL-6 ranged between 0 and 1.5 plaque forming cells per 1000 megakaryocytes (n = 10, mean 0.9/1000 secreting megakaryocytes, examination of 25 000 megakaryocytes), in PG the megakaryocytic spontaneous secretion of this cytokine ranged between 0 and 1.2 plaque forming cells per 1000 megakaryocytes (n = 5, mean 0.6/1000 secreting megakaryocytes, examination of 10 050 megakaryocytes). In contrast, PV megakaryocytes from each of the five patients under study presented a significantly enhanced spontaneous IL-6 secretion (range 11.2-51.3, mean 32.2/1000 plaque forming cells per 1000 megakaryocytes, examination of 12 560 megakaryocytes). Stimulation with rhIL-3 prior to the RHPA resulted in a significant (P Ͻ 0.05) increase in IL-6 secretion in normal (n = 10, range 30.8-72.1, mean 48.0 per 1000 megakaryocytes), examination of 25 000 megakaryocytes) and PG megakaryocytes (n = 5, range 38.2-78.8, mean 61.1 per 1000 megakaryocytes, examination of 11 160 megakaryocytes). On the other side, megakaryocytic IL-6 secretion of all five PV patients decreased after exposure to rhIL-3 (mean 1.1 per 1000 megakaryocytes, range 0.4-6.1/1000, examination of 10 880 megakaryocytes).
Following the observation of a spontaneous IL-6 secretion and a decrease after rhIL-3 administration of PV megakaryocytes, additional experiments using the RT-PCR technique were performed. Active mRNA synthesis was taking place in the megakaryocytes. As shown in Figure 4a , a highly enriched PV megakaryocyte fraction displayed the expression of IL-6 mRNA. Additionally, expression of IL-6R mRNA could be detected. Treatment with rhIL-3 (10 ng/8 h) altered the expression pattern and revealed the presence of IL-6 mRNA in the PV (b) as well as in the normal and in the PG megakaryocyte group (d). Moreover, IL-6R expression was down-regulated (b). In control experiments, no IL-6 or IL-6R mRNA was detectable in megakaryocyte-depleted cell fractions. IL-6 mRNA was always present in parallel studies using the BJAB cell line as a positive control (data not shown). stimulation by the addition of 10 ng/ml rhIL-3 to the serum-free tissue culture medium. After collection of the cells by centrifugation, cellular mRNA was isolated and reverse transcribed. The cDNA was split and subjected to PCR amplification using primers for ␤-actin, IL-6 and IL-6R. Representative data of one experiment are demonstrated. In the PV fraction, IL-6 mRNA and IL-6R mRNA are observable spontaneously while only IL-6 mRNA is detected after rhIL-3 stimulation. In PG, an induction of IL-6 mRNA can only be appreciated after stimulation with rhIL-3.
Discussion
PV is a clonal disorder characterized by a trilinear proliferation of hematopoietic stem cells. Marked thrombocytosis and elevated red blood cell counts are the features that frequently lead to the diagnosis in early stages of the disease. 1, 27, 28 Human megakaryopoiesis presents a complex process involving comittment, differentiation and maturation leading to the formation of polyploid platelet-shedding megakaryocytes. 29 This process is orchestrated by several proliferation and differentiation factors, 30 among which IL-6 plays a pivotal role. In vitro studies point to the fact that this mediator facilitates a promotion of megakaryocytic proliferation and size and, hence, induces a significant shift towards higher ploidy classes. 31 In addition, elevated blood cell counts, thrombocytosis and hepatosplenomegaly of IL-6 -and, even more expressed in IL-6/sIL-6R transgene mice provide persuasive evidence for a central role of this cytokine -receptor complex in the regulation of megakaryopoiesis and erythropoiesis. 6, 32 Megakaryocytes take an active part in the network of IL-6 interactions as they are able to synthesize and secrete IL-6. 14, 33 Prognosis depends mainly on the evolution of secondary myelofibrosis. In previous studies we have found evidence, that the process of myelofibrosis is mediated by cytokine interactions, also. 34 These observations lead us to the hypothesis that altered megakaryocytic secretion patterns of IL-6 are one pathomechanism in PV. Investigating serum levels of IL-6 by ELISA, we were unable to measure significant differences between the normal, the PG and the PV groups under study. Furthermore, in agreement with others, methylcellulose assays on CD34-positive progenitor cells did not present significant differences concerning their proliferative capacity and differentiation. However, immunhistochemistry revealed that a larger proportion of megakaryocytes contain secretable IL-6 in PV as compared to the other groups, suggesting that serum levels alone do not represent a sensitive marker of the disease process. Hence, we set out to employ the RHPA, an extremely sensitive technique that facilitates the detection of IL-6 secretion at the single cell level. 14, 20, 21 Our results unequivocably demonstrate that the rate of IL-6 secreting megakaryocytes is markedly increased in PV as opposed to PG or normal controls. These findings are further corroborated by data derived from RT-PCR experiments on highly enriched megakaryocyte preparations. In these studies, IL-6R could be detected together with IL-6 mRNA, thus rendering an autocrine control most likely.
Other research groups have pointed out that IL-6 synthesis is raised in other myeloproliferative diseases. A large production of IL-6, GM-CSF, M-CSF and G-CSF was reported in a murine variant of a myeloproliferative syndrome. 3 Furthermore, a wealth of data has been accumulated suggesting that IL-6 and GM-CSF act as autocrine growth factors for CML cells under in vitro conditions. 4 Moreover, in the megakaryoblastic leukemia cell line, CMK, the constitutive mRNA expression of IL-6 has been reported. 35 Other experimental studies repeatedly pointed out that megakaryocyte progenitors in CMPDs were hypersensitive to rhIL-3, rhIL-6 and rhGM-CSF. 2, 36, 37 In previous studies, we found that megakaryocytic IL-6 production can be induced by IL-3 stimulation.
14 Having detected a markedly increased megakaryocytic synthesis and secretion of IL-6 in PV, we were interested to find whether production could be further increased by IL-3 stimulation. To our great surprise, megakaryocytes in PV displayed a paradoxical response in that IL-3 lead to a significant down-regulation in these cells. These changes were associated with a down-regulation of IL-6R mRNA.
In conclusion, our experiments have for the first time provided conclusive evidence for a dysregulation of megakaryocytic IL-6 synthesis and secretion in PV. This defect might explain several features of the disease process including hyperploidity consistent with an increase in size and myelofibrosis. [38] [39] [40] Future studies are required to search for abnormalities in the signalling cascade including the transducer gp130, the members of the JAK gene family and STAT factors in PV and to clarify the biological role of IL-6/IL-6R regarding the evolution and clinical presentation of the disease.
